<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1025-028X</journal-id>
<journal-title><![CDATA[Vaccimonitor]]></journal-title>
<abbrev-journal-title><![CDATA[Vaccimonitor]]></abbrev-journal-title>
<issn>1025-028X</issn>
<publisher>
<publisher-name><![CDATA[Finlay Ediciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1025-028X2000000300005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Desarrollo de biomodelos para la evaluación de la inmunidad secretora contra M. tuberculosis en ratones Balb/c]]></article-title>
<article-title xml:lang="en"><![CDATA[Development of Biomodels for the evaluation of the secretory immunity against M tuberculosis in Balb/c mice]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[León]]></surname>
<given-names><![CDATA[Annette]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[Armando]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sarmiento]]></surname>
<given-names><![CDATA[María Elena]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Estévez]]></surname>
<given-names><![CDATA[Pedro]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[Máximo]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[María Elena]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Falero]]></surname>
<given-names><![CDATA[Gustavo]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fariñas]]></surname>
<given-names><![CDATA[Mildrey]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Infante]]></surname>
<given-names><![CDATA[Juan Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ivanyi]]></surname>
<given-names><![CDATA[Juraj]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sierra]]></surname>
<given-names><![CDATA[Gustavo]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Instituto Finlay  ]]></institution>
<addr-line><![CDATA[Ciudad de La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="A02">
<institution><![CDATA[,A02  ]]></institution>
<addr-line><![CDATA[Londres ]]></addr-line>
<country>UK</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2000</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2000</year>
</pub-date>
<volume>9</volume>
<numero>3</numero>
<fpage>24</fpage>
<lpage>30</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1025-028X2000000300005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1025-028X2000000300005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1025-028X2000000300005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Poco se ha estudiado acerca del papel de los anticuerpos específicos, presentes en las secreciones del aparato respiratorio, en la defensa contra patógenos intracelulares, como es el caso de las micobacterias causantes de la tuberculosis en el hombre: Micobacterium tuberculosis, bovis y africanum. Con el objetivo de desarrollar modelos adecuados para evaluar el posible papel de la inmunidad secretoria en la defensa contra la tuberculosis, se desarrollaron dos modelos animales con la utilización de un anticuerpo monoclonal IgA dirigido contra la proteína de 16 kD de M. tuberculosis y M. bovis. En el primer modelo se inocularon ratones Balb/c, por vía subcutánea al nivel de la nuca, con diferentes cantidades de células del hibridoma TBA61, productor de la IgA específica. En un segundo modelo, se inoculó por vía intraperitoneal líquido ascítico correspondiente a este hibridoma obtenido en ratón. En ambos casos se determinó, a diferentes tiempos, la concentración del monoclonal en saliva y sólo en suero para el segundo. En los dos modelos se demostró el paso del monoclonal a la saliva, donde alcanzó la máxima concentración: a los 21 días en los animales inoculados con el hibridoma, y a las 2 horas en saliva y suero en los animales inoculados con el líquido ascítico. Se sugiere, por su sencillez y mayor inocuidad, el uso del segundo modelo para la realización de estudios de reto por vía mucosal.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[The role of specific antibodies found in the respiratory tract secretion, in the defense against intracellular pathogens like mycobacterium causing tuberculosis in man (M. tuberculosis, M. bovis, M. africanum), has not been studied deeply enough. With the purpose of developing suitable experimental models aimed at the assessment of the secretory immunity role in the defense against tuberculosis, two experimental models were developed using IgA monoclonal antibodies directed against the M. tuberculosis and M. bovis. 16 kDa protein. In the first model Balb/c mice were subcutaneously inoculated in the neck with different amounts of TBA61 hibridome cells, which produce the specific IgA. In a second model, this hibridome&#8217;s ascitic fluid, obtained from mice, was intraperitoneally inoculated. In both cases, we determined, in different moments, the monoclonal concentration in saliva and only in the second one; we determined the concentration in serum. In the two models we demonstrated the monoclonal&#8217;s pass to the saliva, reaching its maximum concentration at 21 days in the animals inoculated with the hibridome and at two hours in saliva and serum in the animals inoculated with ascitic fluid. Due to its simplicity and innocuousness, we recommend the use of the second model for challenging experiments through the mucosal way.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Tuberculosis]]></kwd>
<kwd lng="es"><![CDATA[inmunidad de mucosa]]></kwd>
<kwd lng="es"><![CDATA[anticuerpo]]></kwd>
<kwd lng="es"><![CDATA[hibridoma]]></kwd>
<kwd lng="es"><![CDATA[IgA]]></kwd>
<kwd lng="en"><![CDATA[Tuberculosis]]></kwd>
<kwd lng="en"><![CDATA[mucosal immunity]]></kwd>
<kwd lng="en"><![CDATA[Antibodies]]></kwd>
<kwd lng="en"><![CDATA[hibridome]]></kwd>
<kwd lng="en"><![CDATA[IgA]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTICULOS ORIGINALES</b></font></p>     <p align="right">&nbsp;</p>     <p align="right"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong><font size="4">Desarrollo de biomodelos para la evaluaci&oacute;n de la    inmunidad secretora contra M. tuberculosis en ratones    Balb/c.</font>    <br> </strong></font></p>     <p align="right">&nbsp;</p>     <p align="right"><strong><font size="3" face="Verdana, Arial, Helvetica, sans-serif">Development of Biomodels for the evaluation of the secretory immunity against M tuberculosis in Balb/c mice.</font></strong></p>     <p>&nbsp;</p>     <p><strong><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Annette Le&oacute;n1, Armando Acosta1, Mar&iacute;a Elena Sarmiento1, Pedro Est&eacute;vez1, M&aacute;ximo Mart&iacute;nez1, Mar&iacute;a    <br>   Elena P&eacute;rez1, Gustavo Falero1, Mildrey Fari&ntilde;as1, Juan Francisco Infante1, Juraj Ivanyi2, Gustavo Sierra1.</font></strong><font size="2" face="Verdana, Arial, Helvetica, sans-serif">    <br>       </font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Instituto Finlay, Centro de Investigaci&oacute;n-Producci&oacute;n de Vacunas y Sueros. Ciudad de La Habana, Cuba.    <br>   E-mail:<a href="emailto:aleon@finlay.edu.cu">aleon@finlay.edu.cu</a>    <br> 2. Departamento de Medicina Oral y Patolog&iacute;a. Guy&rsquo;s Hospital. Londres. UK.</font></p> <hr>     <p align="justify"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>RESUMEN</strong>    <br> </font></p>     <p align="justify"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Poco se ha estudiado acerca del papel de los anticuerpos espec&iacute;ficos, presentes en las secreciones del aparato    respiratorio, en la defensa contra pat&oacute;genos intracelulares, como es el caso de las micobacterias causantes de la    tuberculosis en el hombre: Micobacterium tuberculosis, bovis y africanum. Con el objetivo de desarrollar modelos    adecuados para evaluar el posible papel de la inmunidad secretoria en la defensa contra la tuberculosis, se    desarrollaron dos modelos animales con la utilizaci&oacute;n de un anticuerpo monoclonal IgA dirigido contra la prote&iacute;na    de 16 kD de M. tuberculosis y M. bovis. En el primer modelo se inocularon ratones Balb/c, por v&iacute;a subcut&aacute;nea al    nivel de la nuca, con diferentes cantidades de c&eacute;lulas del hibridoma TBA61, productor de la IgA espec&iacute;fica. En un    segundo modelo, se inocul&oacute; por v&iacute;a intraperitoneal l&iacute;quido asc&iacute;tico correspondiente a este hibridoma obtenido en    rat&oacute;n. En ambos casos se determin&oacute;, a diferentes tiempos, la concentraci&oacute;n del monoclonal en saliva y s&oacute;lo en    suero para el segundo. En los dos modelos se demostr&oacute; el paso del monoclonal a la saliva, donde alcanz&oacute; la    m&aacute;xima concentraci&oacute;n: a los 21 d&iacute;as en los animales inoculados con el hibridoma, y a las 2 horas en saliva y    suero en los animales inoculados con el l&iacute;quido asc&iacute;tico. Se sugiere, por su sencillez y mayor inocuidad, el uso    del segundo modelo para la realizaci&oacute;n de estudios de reto por v&iacute;a mucosal.    <br> </font></p>     <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>Palabras claves:</strong> Tuberculosis, inmunidad de mucosa, anticuerpo, hibridoma, IgA.</font></p> <hr>     <p align="justify"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">  <strong>ABSTRACT</strong></font></p>     <p align="justify"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> The role of specific antibodies found in the respiratory tract secretion, in the defense against intracellular    pathogens like mycobacterium causing tuberculosis in man (M. tuberculosis, M. bovis, M. africanum), has not    been studied deeply enough. With the purpose of developing suitable experimental models aimed at the    assessment of the secretory immunity role in the defense against tuberculosis, two experimental models were    developed using IgA monoclonal antibodies directed against the M. tuberculosis and M. bovis. 16 kDa protein.    In the first model Balb/c mice were subcutaneously inoculated in the neck with different amounts of TBA61    hibridome cells, which produce the specific IgA. In a second model, this hibridome&rsquo;s ascitic fluid, obtained from    mice, was intraperitoneally inoculated. In both cases, we determined, in different moments, the monoclonal    concentration in saliva and only in the second one; we determined the concentration in serum. In the two    ]]></body>
<body><![CDATA[<br>   models we demonstrated the monoclonal&rsquo;s pass to the saliva, reaching its maximum concentration at 21 days    in the animals inoculated with the hibridome and at two hours in saliva and serum in the animals inoculated    with ascitic fluid. Due to its simplicity and innocuousness, we recommend the use of the second model for    challenging experiments through the mucosal way.    <br> </font></p>     <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>Key words:</strong> Tuberculosis, mucosal immunity, Antibodies, hibridome, IgA</font></p> <hr>     <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">texto completo en pdf</font></p>     <P  ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><B>REFERENCIAS</B> </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Orme IM. Progress in the development of new vaccines against tuberculosis. Int J Tuberc Lung Dis 1997; 1(2):95-100. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Huebner RE. Bacillus of Calmette and Guerin (BCG) vaccine. New York: Ediciones Rom WN y Garay S. 1996. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Teitelbaum R, Glatman A, Chen B, Robbins JB, Unanue E, Bloom BR. AmAb recognizing a surface antigen of M. tuberculosis enhances host survival. Microbiology 1998; 95(26):15688-15693. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Freedman GA, Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against M. tuberculosis. Clin Microbiol Rev 1998; 11:514-532. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Winner L, Weltzin LA, Mekalanos JJ, Neutra MR. New model for analysis of mucosal immunity: intestinal secretion of specific monoclonal immunoglobulin A from hybridoma tumors protects against V. cholerae infection. Infect Immun 1991; 59:977-982. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Michetti P, Mahan MJ, Slauch MJ, Mekalanos JJ, Neutra MR. Monoclonal Secretory Immunoglobulin A Protects Mice against Oral Challenge with the Invasive Pathogen S. typhimurium. Infection and Immunity 1992; 60(5):1786-1792. </font>    <P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Mestecky J. Lue C ad Russell MW. Selective transport of IgA. Cellular and Molecular aspect. Gastroenterol Clin North Am 1991; 20:441-471. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. McIntosh K, Master HB, Orr I, Chao RK, Barking RM. The immunological response to infection with respiratory syncitial virus in infants. J Infect Dis 1978; 138:24-32. </font>    <!-- ref --><P  ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Watt PJ, Robinson BS, Pringle DA. Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncitial virus vaccines. Vaccine 1990; 8:1231-1236. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Piazza FM, John MG, Otolini HJ, Schmidt MER, Darnell VG, Prince GA. Immunotherapy of respiratory syncitial virus infection in cotton rats using IgG in small-particle aerosol. J Infect Dis 1992; 166:1422-1424. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Walsh EE, Schlesinger MW. Protection from respiratory syncitial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun 1984; 43:756-758. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Mestecky J. The common mucosal immune system and the current strategies for inductionof immune response in external secretions. J. Clin. Immun. 1987; 7:265-276. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. McNabb PC, Tomasi TB. Host defense mechanisms at mucosal surfaces. Annu Rev Microbiol 1981; 35:477-496. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Steinmetz I, Albretcht F, Haussler S, Brenneke B. Monoclonal IgA class-switch variantsagainst bacterial surface antigens: molecular forms and transport into murine respiratory secretions. Eur J Immunol 1994; 24:2855-2862. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Freedman AG, Casadevall A. Serum therapy for Tuberculosis Revicited: Reappraisal of the Role of antibody-mediated Immunity against Mycobacterium tuberculosis. Clinical Microbiology Reviews 1998; 11(3): 514-532. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Falero G, Challacombe S, Rhaman D, Mistry M, Dougan G, Acosta A, Ivanyi J. Transmission of IgA and IgG monoclonal antibodies to mucosal fluids following intranasal or parenteral delivery. Int Arch Allergy Immunol 2000; 122(2):143-150. </font>    <p>&nbsp; </p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orme]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Progress in the development of new vaccines against tuberculosis]]></article-title>
<source><![CDATA[Int J Tuberc Lung Dis]]></source>
<year>1997</year>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>95-100</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huebner]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<source><![CDATA[Bacillus of Calmette and Guerin (BCG) vaccine]]></source>
<year>1996</year>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Rom WN y Garay]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teitelbaum]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Glatman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Robbins]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Unanue]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bloom]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[AmAb recognizing a surface antigen of M: tuberculosis enhances host survival]]></article-title>
<source><![CDATA[Microbiology]]></source>
<year>1998</year>
<volume>95</volume>
<numero>26</numero>
<issue>26</issue>
<page-range>15688-15693</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freedman]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Casadevall]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against M tuberculosis]]></article-title>
<source><![CDATA[Clin Microbiol Rev]]></source>
<year>1998</year>
<volume>11</volume>
<page-range>514-532</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Winner]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Weltzin]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Mekalanos]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Neutra]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[New model for analysis of mucosal immunity: intestinal secretion of specific monoclonal immunoglobulin A from hybridoma tumors protects against V]]></article-title>
<source><![CDATA[cholerae infection. Infect Immun]]></source>
<year>1991</year>
<volume>59</volume>
<page-range>977-982</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Michetti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mahan]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Slauch]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mekalanos]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Neutra]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Monoclonal Secretory Immunoglobulin A Protects Mice against Oral Challenge with the Invasive Pathogen S typhimurium]]></article-title>
<source><![CDATA[Infection and Immunity]]></source>
<year>1992</year>
<volume>60</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1786-1792</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mestecky]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lue]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Russell]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Selective transport of IgA: Cellular and Molecular aspect]]></article-title>
<source><![CDATA[Gastroenterol Clin North Am]]></source>
<year>1991</year>
<volume>20</volume>
<page-range>441-471</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McIntosh]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Master]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
<name>
<surname><![CDATA[Orr]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Chao]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Barking]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The immunological response to infection with respiratory syncitial virus in infants]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>1978</year>
<volume>138</volume>
<page-range>24-32</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Watt]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Pringle]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncitial virus vaccines]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>1990</year>
<volume>8</volume>
<page-range>1231-1236</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piazza]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[John]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Otolini]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[MER]]></given-names>
</name>
<name>
<surname><![CDATA[Darnell]]></surname>
<given-names><![CDATA[VG]]></given-names>
</name>
<name>
<surname><![CDATA[Prince]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Immunotherapy of respiratory syncitial virus infection in cotton rats using IgG in small-particle aerosol]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>1992</year>
<volume>166</volume>
<page-range>1422-1424</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Schlesinger]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Protection from respiratory syncitial virus infection in cotton rats by passive transfer of monoclonal antibodies]]></article-title>
<source><![CDATA[Infect Immun]]></source>
<year>1984</year>
<volume>43</volume>
<page-range>756-758</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mestecky]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The common mucosal immune system and the current strategies for inductionof immune response in external secretions]]></article-title>
<source><![CDATA[J Clin Immun]]></source>
<year>1987</year>
<volume>7</volume>
<page-range>265-276</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McNabb]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Tomasi]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Host defense mechanisms at mucosal surfaces]]></article-title>
<source><![CDATA[Annu Rev Microbiol]]></source>
<year>1981</year>
<volume>35</volume>
<page-range>477-496</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steinmetz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Albretcht]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Haussler]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Brenneke]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Monoclonal IgA class-switch variantsagainst bacterial surface antigens: molecular forms and transport into murine respiratory secretions]]></article-title>
<source><![CDATA[Eur J Immunol]]></source>
<year>1994</year>
<volume>24</volume>
<page-range>2855-2862</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freedman]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Casadevall]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Serum therapy for Tuberculosis Revicited: Reappraisal of the Role of antibody-mediated Immunity against Mycobacterium tuberculosis]]></article-title>
<source><![CDATA[Clinical Microbiology Reviews]]></source>
<year>1998</year>
<volume>11</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>514-532</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Falero]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Challacombe]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rhaman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mistry]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dougan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ivanyi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Transmission of IgA and IgG monoclonal antibodies to mucosal fluids following intranasal or parenteral delivery]]></article-title>
<source><![CDATA[Int Arch Allergy Immunol]]></source>
<year>2000</year>
<volume>122</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>143-150</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
